Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.000427 | uM | 10261.024 | 1.0328 | 1.0297 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.00213 | uM | 10261.024 | 0.9895 | 0.9904 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 10261.024 | 0.1572 | -0.1428 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0533 | uM | 10261.024 | 0.9671 | 0.9696 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.267 | uM | 10261.024 | 1.0649 | 1.0584 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 1.33 | uM | 10261.024 | 0.9113 | 0.9167 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 6.67 | uM | 10261.024 | 0.7407 | 0.7432 | 2.1838 | |
| BT-549 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 33.3 | uM | 10261.024 | 0.3830 | 0.2887 | 2.1838 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7805.016 | 1.0359 | 1.0594 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7805.016 | 1.0312 | 1.0516 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7805.016 | 1.0057 | 1.0094 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7805.016 | 1.0567 | 1.0936 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7805.016 | 1.0085 | 1.0141 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 7805.016 | 1.0453 | 1.0748 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7805.016 | 0.9967 | 0.9945 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7805.016 | 1.0188 | 1.0312 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7805.016 | 0.6330 | 0.3689 | 1.2059 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9210.024 | 1.0376 | 1.0867 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9210.024 | 0.9707 | 0.9328 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9210.024 | 1.0303 | 1.0699 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9210.024 | 0.8801 | 0.7269 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9210.024 | 1.0086 | 1.0198 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 9210.024 | 1.0403 | 1.0929 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 9210.024 | 1.0496 | 1.1144 | 0.8697 | |
| CAMA-1 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 9210.024 | 0.9750 | 0.9427 | 0.8697 |